Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.

Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu S, Singh S, Poddar M, Monga JS, Liu P, Oertel M, Ranganathan S, Singhi A, Rebouissou S, Zucman-Rossi J, Ribback S, Calvisi D, Qvartskhava N, Görg B, Häussinger D, Chen X, Monga SP.

Cell Metab. 2019 Jan 28. pii: S1550-4131(19)30002-6. doi: 10.1016/j.cmet.2019.01.002. [Epub ahead of print]

PMID:
30713111
2.

Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma.

Bárcena-Varela M, Caruso S, Llerena S, Álvarez-Sola G, Uriarte I, Latasa MU, Urtasun R, Rebouissou S, Alvarez L, Jimenez M, Santamaría E, Rodriguez-Ortigosa C, Mazza G, Rombouts K, San José-Eneriz E, Rabal O, Agirre X, Iraburu M, Santos-Laso A, Banales JM, Zucman-Rossi J, Prósper F, Oyarzabal J, Berasain C, Ávila MA, Fernández-Barrena MG.

Hepatology. 2019 Feb;69(2):587-603. doi: 10.1002/hep.30168. Epub 2019 Jan 4.

PMID:
30014490
3.

Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas.

Nault JC, Couchy G, Caruso S, Meunier L, Caruana L, Letouzé E, Rebouissou S, Paradis V, Calderaro J, Zucman-Rossi J.

Hepatology. 2018 Sep;68(3):964-976. doi: 10.1002/hep.29884. Epub 2018 Jun 6.

PMID:
29572896
4.

Reply.

Rebouissou S, Bioulac-Sage P, Nault JC, Calderaro J, Zucman-Rossi J.

Hepatology. 2017 Dec;66(6):2093-2094. doi: 10.1002/hep.29563. Epub 2017 Nov 6. No abstract available.

PMID:
28961324
5.

Note of caution: Contaminations of hepatocellular cell lines.

Rebouissou S, Zucman-Rossi J, Moreau R, Qiu Z, Hui L.

J Hepatol. 2017 Nov;67(5):896-897. doi: 10.1016/j.jhep.2017.08.002. Epub 2017 Aug 12. No abstract available.

PMID:
28807831
6.

A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.

Fan Y, Arechederra M, Richelme S, Daian F, Novello C, Calderaro J, Di Tommaso L, Morcrette G, Rebouissou S, Donadon M, Morenghi E, Zucman-Rossi J, Roncalli M, Dono R, Maina F.

Hepatology. 2017 Nov;66(5):1644-1661. doi: 10.1002/hep.29304. Epub 2017 Sep 29.

PMID:
28586114
7.

Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro.

Rebouissou S, La Bella T, Rekik S, Imbeaud S, Calatayud AL, Rohr-Udilova N, Martin Y, Couchy G, Bioulac-Sage P, Grasl-Kraupp B, de Koning L, Ganne-Carrié N, Nault JC, Ziol M, Zucman-Rossi J.

Clin Cancer Res. 2017 Aug 1;23(15):4364-4375. doi: 10.1158/1078-0432.CCR-16-3118. Epub 2017 Feb 28.

8.

Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.

Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S; GENTHEP Investigators, Bioulac-Sage P, Letouzé E, Zucman-Rossi J.

Gastroenterology. 2017 Mar;152(4):880-894.e6. doi: 10.1053/j.gastro.2016.11.042. Epub 2016 Dec 7.

9.

Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression.

Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, Nault JC, Couchy G, Laurent A, Balabaud C, Bioulac-Sage P, Zucman-Rossi J.

Hepatology. 2016 Dec;64(6):2047-2061. doi: 10.1002/hep.28638. Epub 2016 Jun 11.

PMID:
27177928
10.

NRF2/KEAP1 and Wnt/β-catenin in the multistep process of liver carcinogenesis in humans and rats.

Nault JC, Rebouissou S, Zucman Rossi J.

Hepatology. 2015 Sep;62(3):677-9. doi: 10.1002/hep.27828. Epub 2015 Jun 9. No abstract available.

PMID:
25846427
11.

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J.

Nat Genet. 2015 May;47(5):505-511. doi: 10.1038/ng.3252. Epub 2015 Mar 30.

12.

A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.

Nault JC, De Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, Azoulay D, Saric J, Blanc JF, Balabaud C, Bioulac-Sage P, Laurent A, Laurent-Puig P, Llovet JM, Zucman-Rossi J.

Gastroenterology. 2013 Jul;145(1):176-187. doi: 10.1053/j.gastro.2013.03.051. Epub 2013 Apr 6.

PMID:
23567350
13.

Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.

Calderaro J, Labrune P, Morcrette G, Rebouissou S, Franco D, Prévot S, Quaglia A, Bedossa P, Libbrecht L, Terracciano L, Smit GP, Bioulac-Sage P, Zucman-Rossi J.

J Hepatol. 2013 Feb;58(2):350-7. doi: 10.1016/j.jhep.2012.09.030. Epub 2012 Oct 6.

PMID:
23046672
14.

HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines.

Pelletier L, Rebouissou S, Vignjevic D, Bioulac-Sage P, Zucman-Rossi J.

BMC Cancer. 2011 Oct 5;11:427. doi: 10.1186/1471-2407-11-427.

15.

Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis.

Pelletier L, Rebouissou S, Paris A, Rathahao-Paris E, Perdu E, Bioulac-Sage P, Imbeaud S, Zucman-Rossi J.

Hepatology. 2010 Feb;51(2):557-66. doi: 10.1002/hep.23362.

PMID:
20041408
16.

[Gp130-activating mutations in inflammatory liver adenomas].

Zucman-Rossi J, Amessou M, Bioulac-Sage P, Rebouissou S.

Med Sci (Paris). 2008 Dec;24(12):1113-4. doi: 10.1051/medsci/200824121113. French. No abstract available.

17.

Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.

Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, Izard T, Balabaud C, Bioulac-Sage P, Zucman-Rossi J.

Nature. 2009 Jan 8;457(7226):200-4. doi: 10.1038/nature07475. Epub 2008 Nov 19.

18.

The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules.

Rebouissou S, Couchy G, Libbrecht L, Balabaud C, Imbeaud S, Auffray C, Roskams T, Bioulac-Sage P, Zucman-Rossi J.

J Hepatol. 2008 Jul;49(1):61-71. doi: 10.1016/j.jhep.2008.03.013. Epub 2008 Apr 18.

19.

MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.

Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J.

Hepatology. 2008 Jun;47(6):1955-63. doi: 10.1002/hep.22256.

20.

Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma.

Rebouissou S, Bioulac-Sage P, Zucman-Rossi J.

J Hepatol. 2008 Jan;48(1):163-70. Epub 2007 Oct 30. Review.

PMID:
17997499

Supplemental Content

Loading ...
Support Center